Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

A new study published in The Lancet journal showed that patients with type 2 diabetes and symptomatic peripheral arterial ...

Methods A comprehensive search strategy was conducted to identify relevant studies focused on walking cadence and intensity for adults. Identified studies (n=38) included controlled (n=11), ...

Key Laboratory of Food Nutrition and Safety of SDNU, Provincial Key Laboratory of Animal Resistant Biology, College of Life Science, Shandong Normal University, Jinan, China Background: The purpose of ...

Walking emerges as a potent tool for blood sugar management, particularly beneficial for those with diabetes or prediabetes. Studies reveal that brisk walking significantly lowers diabetes risk ...

As a result, a market for cheaper, off-brand versions of their active ingredients — semaglutide and tirzepatide — has proliferated, serving people looking for weight loss drugs at a fraction ...

Walking has never been hotter. Whether it’s walking clubs, fitness walkers advocating the health benefits on social media, or just the growing realization that taking a walk is a great way to ...

The primary outcome of this study was a change in maximum walking distance after 52 weeks, while a key secondary outcome was improvement in symptoms and quality of life. According to study results, ...

Veru's Phase 2b study shows enobosarm combined with semaglutide improves safety, reduces gastrointestinal issues, and promotes fat loss while preserving lean mass. There is a potential risk that ...

Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY ...

What is it? A medication called semaglutide, which is sold under different brand names, including Ozempic, approved in 2017 for treating type 2 diabetes, and Wegovy, approved just last year for ...